リソソームアルファグルコシダーゼ治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Lysosomal Alpha Glucosidase - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0511
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:83
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Lysosomal Alpha Glucosidase – Pipeline Review, H2 2019
Summary

According to the recently published report ‘Lysosomal Alpha Glucosidase – Pipeline Review, H2 2019′; Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Lysosomal alpha-glucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects in this gene lead to glycogen storage disease II or Pompe disease.

The report ‘Lysosomal Alpha Glucosidase – Pipeline Review, H2 2019′ outlays comprehensive information on the Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 9 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Pompe Disease.

Scope

- The report provides a snapshot of the global therapeutic landscape for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)
- The report reviews Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics and enlists all their major and minor projects
- The report assesses Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Overview
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Companies Involved in Therapeutics Development
Actus Therapeutics Inc
Amicus Therapeutics Inc
Audentes Therapeutics Inc
AVROBIO Inc
Etubics Corp
Genzyme Corp
Greenovation Biotech GmbH
JCR Pharmaceuticals Co Ltd
NanoMedSyn SAS
Oxyrane Belgium NV
Pharming Group NV
Spark Therapeutics Inc
Valerion Therapeutics LLC
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Drug Profiles
(alglucosidase alfa + miglustat) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACTUS-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-845 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avalglucosidase alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVRRD-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 1 to Activate Acid Alpha-Glucosidase for Pompe Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 2 to Activate Acid Alpha-Glucosidase for Pompe Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GAA for Pompe Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GAA for Pompe Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-162 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOSS-GAA – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXY-2810 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-004 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Alpha Glucosidase Replacement for Pompe Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPK-3006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-1221 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Dormant Products
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Discontinued Products
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) – Product Development Milestones
Featured News & Press Releases
Oct 02, 2019: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society
Oct 01, 2019: Amicus Therapeutics to present at Upcoming Medical and Investor Conferences in October 2019
Apr 30, 2019: Amicus Therapeutics presents positive preclinical pompe disease gene therapy data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Apr 15, 2019: Amicus Therapeutics to present preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Mar 20, 2019: Amicus Therapeutics issued two U.S. patents for pompe enzyme ATB200
Feb 28, 2019: WUXI Biologics congratulates Amicus on receiving FDA breakthrough therapy designation for AT-GAA
Feb 25, 2019: U.S. FDA grants Breakthrough Therapy Designation to Amicus’ AT-GAA in late onset pompe disease
Feb 11, 2019: WuXi Biologics and Amicus sign exclusive manufacturing partnership
Feb 07, 2019: Sanofi announces additional data on avalglucosidase alfa in Pompe disease
Feb 07, 2019: Sanofi announces new safety data for investigational avalglucosidase alfa in patients with Pompe disease
Feb 05, 2019: Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium
Jan 31, 2019: Spark Therapeutics announces presentation of preclinical data in Pompe disease at 15th annual WORLDSymposium
Jan 30, 2019: Sanofi presents Avalglucosidase Alfa Development Program at 15th Annual WORLDSymposium 2019
Jan 29, 2019: Actus Begins Gene Therapy Trial for Pompe Disease
Jan 07, 2019: Audentes Therapeutics provides update on Pompe disease program AT-845
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Actus Therapeutics Inc, H2 2019
Pipeline by Amicus Therapeutics Inc, H2 2019
Pipeline by Audentes Therapeutics Inc, H2 2019
Pipeline by AVROBIO Inc, H2 2019
Pipeline by Etubics Corp, H2 2019
Pipeline by Genzyme Corp, H2 2019
Pipeline by Greenovation Biotech GmbH, H2 2019
Pipeline by JCR Pharmaceuticals Co Ltd, H2 2019
Pipeline by NanoMedSyn SAS, H2 2019
Pipeline by Oxyrane Belgium NV, H2 2019
Pipeline by Pharming Group NV, H2 2019
Pipeline by Spark Therapeutics Inc, H2 2019
Pipeline by Valerion Therapeutics LLC, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

【掲載企業】

Actus Therapeutics Inc
Amicus Therapeutics Inc
Audentes Therapeutics Inc
AVROBIO Inc
Etubics Corp
Genzyme Corp
Greenovation Biotech GmbH
JCR Pharmaceuticals Co Ltd
NanoMedSyn SAS
Oxyrane Belgium NV
Pharming Group NV
Spark Therapeutics Inc
Valerion Therapeutics LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[リソソームアルファグルコシダーゼ治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆